Pharmaceutical Products: 70%
Animal Health: 20%
Dietary Supplements: 10%

Spain: 45%
Portugal: 25%
Latin America: 15%

Faes Farma, S.A. generates the majority of its revenue from the sale of pharmaceutical products, accounting for approximately 70% of total revenue. Another important area is animal health, followed by dietary supplements.

Geographically, Spain is the largest market for Faes Farma, followed by Portugal and Latin America. These markets are crucial for the company as they together generate the majority of the revenue.

Production Sites:

• Spain
• Portugal
• Colombia

Faes Farma, S.A. mainly produces its pharmaceutical products in Spain, where the company's headquarters are also located. In addition, the company has production facilities in Portugal and Colombia, enabling it to efficiently serve both the European and Latin American markets.

This geographical diversification in production helps Faes Farma optimize its supply chains and better meet market demand in different regions.

Revenue Growth: 8.5% (estimated for 2026)

Profit Growth: 7.2% (estimated for 2026)

Faes Farma, S.A. pursues a growth strategy based on several pillars. Firstly, the company focuses on expanding its product portfolio through the development of new pharmaceutical products and the optimization of existing medications. This is intended to be achieved through increased investments in research and development.

Secondly, Faes Farma is concentrating on geographical expansion, particularly in emerging markets in Latin America and Asia. Through strategic partnerships and acquisitions, the company plans to strengthen its market presence in these regions.

Additionally, Faes Farma emphasizes improving operational efficiency to optimize cost structure and increase profit margins. This includes implementing new technologies and processes in production and logistics.

This strategy aims to sustainably increase both revenue and profit growth in the coming years.

Main raw materials: Pharmaceutical active ingredients, excipients, packaging materials
Countries of origin: India, China, Germany, USA

Faes Farma, S.A. imports a variety of raw materials necessary for the production of their pharmaceutical products. The main raw materials include pharmaceutical active ingredients and excipients used in the manufacturing of medications.

India and China are significant suppliers of pharmaceutical active ingredients due to their strong pharmaceutical industry and cost-effective production capabilities. Germany and the USA also supply specialized pharmaceutical products and materials essential for the production of high-quality medications.

In addition, Faes Farma sources packaging materials crucial for the safe transportation and storage of their products from various international markets. This diversification of supply chains helps the company minimize risks and ensure production continuity.

Market share in the industry: 8% (2025, estimate)
Research and development ratio: 7.5% of revenue (2025)
EBITDA margin: 28% (2025)

Faes Farma, S.A. has established a solid competitive advantage in the pharmaceutical industry through a strong focus on research and development. With a research and development ratio of 7.5% of revenue, the company significantly invests in the development of new drugs and therapies, leading to a robust pipeline of innovative products.

The 28% EBITDA margin demonstrates that Faes Farma operates efficiently and is able to generate high profits from its revenues. This indicates strong operational efficiency and cost discipline compared to many competitors.

In addition, Faes Farma benefits from a diversified product portfolio and a strong presence in multiple international markets, making the company more resilient to market fluctuations. Together, these factors give Faes Farma a sustainable competitive advantage in the pharmaceutical industry.

Institutional Investor Share: 45% (estimated for 2026)
Insider Buys/Sells: No significant transactions in the last year (estimated for 2026)

The institutional investor share in Faes Farma, S.A. is estimated to be around 45%. This suggests that almost half of the shares are held by large institutional investors, indicating a certain level of trust in the company's stability and growth potential.

In 2026, there were no significant insider transactions, indicating that the management and other insiders do not currently expect major changes in the company's valuation. This stability can be seen as a positive signal for investors, as it reflects confidence in the current corporate strategy.

Market share of Faes Farma, S.A.: Estimate 2-3% (2026)

Main competitors and their market shares:

1. Grifols, S.A.: 10-12%
2. Almirall, S.A.: 8-10%
3. PharmaMar, S.A.: 5-7%
4. Rovi, S.A.: 4-6%
5. Reig Jofre, S.A.: 3-5%

Faes Farma, S.A. has a moderate market share compared to its larger competitors. The market share of Faes Farma is relatively small, indicating strong competition in the industry.

Moat of Faes Farma, S.A.: Faes Farma has a certain moat due to its specialized products and an established presence in specific therapeutic areas. The advantage lies in niche focus and the ability to operate in specific markets with less competition.

Compared to larger competitors like Grifols, which have a broader product portfolio and a stronger international presence, the moat of Faes Farma is less pronounced. Companies like Grifols and Almirall have a significant advantage due to their size, research capabilities, and global reach.

Overall, Faes Farma has a limited but existing moat, which is, however, surpassed by larger and more diversified competitors.

Revenue Growth: 8.5% (2025) Profit Growth: 7.2% (2025) Research & Development Expenses: 12% of revenue (2025)

Faes Farma, S.A. achieved a solid revenue growth of 8.5% in 2025, attributed to successful expansion into new markets and the introduction of new products. The 7.2% profit growth indicates that the company is able to increase its profitability despite higher investments in research and development.

The expenses for research and development account for 12% of revenue, signaling a strong focus on innovation and future growth potential. This could lead to a stronger market position and new revenue streams in the long term.

In summary, Faes Farma, S.A. presents an attractive investment opportunity due to its solid financial performance and strategic investments in research and development. However, potential investors should also consider external factors such as regulatory changes and market risks.

Dividend Yield: 3.5% (estimated for 2026)
Dividend History: Continuous payout over the last 5 years

Faes Farma, S.A. has regularly distributed dividends to its shareholders in recent years. The dividend yield is currently around 3.5%, which can be considered attractive compared to other companies in the industry.

The reliability of dividend payment is supported by the stable financial performance of the company. Faes Farma has experienced solid revenue and profit growth in recent years, enabling the continuous distribution of dividends. Analysts expect that the company will be able to continue paying dividends at a similar level in the coming years, provided that no significant economic or company-specific challenges arise.